In a bid to expand its Respiratory and Monitoring Solutions products portfolio, Covidien plc (COV) has launched a new capnography solution, the Capnostream 20p bedside monitor. This positive news is expected to boost investor confidence in the stock. The company’s stock returned a modest 19.9% to its investors on a year-over-year basis.
The new device, equipped with Covidien’s Microstream technology, is capable of detecting cardiopulmonary complications at an early stage, thereby enhancing patient safety in clinical settings.
For almost two decades, clinicians have depended on COV’s Microstream technology to effectively monitor oxygenation and ventilation. It assists doctors to manage sedation levels and deliver proper doses of opioids for pain management. Moreover, the Apnea-Sat Alert algorithm feature of the Capnostream 20p bedside monitor measures and reports recurring apnea (a temporary condition in which a patient’s breathing stops for more than 10 seconds) and oxygen de-saturation fluctuations.
According to studies, 88% of hospitalized patients may be at risk of recurrent apneas. Yet, out of such large numbers, only few cases are identified and treated. Management claims that the Capnostream 20p bedside monitor increases apnea detection rate, thereby raising standards of care. The device is compliant with the ISO alarm standards and can be easily installed without hampering clinical workflow.
Recently, COV launched two vessel sealing products that are superior to their predecessors in terms of handling, control and performance. The products are LigaSure Impact curved large jaw open sealer/divider LF4318 and LigaSure blunt tip laparoscopic sealer/divider LF1637.
The LigaSure Impact device promises an advanced surgical experience with improved visibility, more intuitive jaw positioning and enhanced ergonomics. On the other hand, the LigaSure blunt tip laparoscopic sealer/divider ensures better handling, and compact and ergonomic grip offering better comfort and control for various hand sizes.
Both the products have received 510(k) clearance from U.S. Food and Drug Administration (:FDA) earlier this year. They are designed for colorectal, general, gynecologic, urologic and thoracic surgeries.
Covidien currently has a Zacks Rank #3 (Hold). While we choose to remain on the sidelines regarding COV, medical product companies such as INSYS Therapeutics, Inc. (INSY), Bio-Rad Laboratories, Inc. (BIO) and Boston Scientific Corp. (BSX) are expected to do well. While INSY and BIO carry a Zacks Rank #1 (Strong Buy), BSX has a Zacks Rank #2 (Buy).Read the Full Research Report on COV
Read the Full Research Report on INSY
Read the Full Research Report on BSX
Read the Full Research Report on BIO
Zacks Investment Research
- Health Care Industry
- Finance Trading